<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664322</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00122-47</org_study_id>
    <secondary_id>CPP-CS 001/2015</secondary_id>
    <nct_id>NCT04664322</nct_id>
  </id_info>
  <brief_title>High-flow Oxygen Therapy vs Non-invasive Ventilation: Comparison of Alveolar Recruitment in Acute Respiratory Failure</brief_title>
  <acronym>IRAvista</acronym>
  <official_title>High-flow Oxygen Therapy Versus Non-invasive Ventilation: a Randomised Physiological Cross-over Study of Alveolar Recruitment in Acute Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This physiological study showed an increase in regional ventilation with NIV but no&#xD;
      difference in alveolar recruitment as compared to HFNC in patients with hypoxemic ARF.&#xD;
      Although NIV provided better oxygenation than HFNC, the effect on lung volumes could explain&#xD;
      the potentially deleterious effect of NIV in hypoxemic ARF, reinforcing the recently&#xD;
      developed concept of patient self-inflicted lung injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: High-flow nasal cannula (HFNC) oxygen therapy has recently shown clinical&#xD;
      benefits in hypoxemic acute respiratory failure (ARF) patients, while the interest of&#xD;
      non-invasive ventilation (NIV) remains debated. The primary endpoint was to compare alveolar&#xD;
      recruitment using global end-expiratory electrical lung impedance (EELI) between HFNC and&#xD;
      NIV. Secondary endpoints compared regional EELI, lung volumes (global and regional tidal&#xD;
      volume variation (TV)), respiratory parameters, hemodynamic tolerance, dyspnea and patient&#xD;
      comfort between HFNC and NIV, relative to face mask (FM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Actual">February 19, 2018</completion_date>
  <primary_completion_date type="Actual">February 13, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>global EELI</measure>
    <time_frame>after 5 minutes of stable breathing with the oxygenation technic</time_frame>
    <description>measurement of global end respiratory lung impedance with non invasive ventilation vs with high flow nasal canulae oxygen therapy, standard unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROI EELI</measure>
    <time_frame>after 5 minutes of stable breathing with the oxygenation technic</time_frame>
    <description>measurement of regional of interest (ROI) end respiratory lung impedance with non invasive ventilation vs with high flow nasal canulae oxygen therapy, standard unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global TV</measure>
    <time_frame>after 5 minutes of stable breathing with the oxygenation technic</time_frame>
    <description>measurement of global tidal variation (TV) with non invasive ventilation vs with high flow nasal canulae oxygen therapy, standard unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROI TV</measure>
    <time_frame>after 5 minutes of stable breathing with the oxygenation technic</time_frame>
    <description>measurement of regional tidal variation with non invasive ventilation vs with high flow nasal canulae oxygen therapy, standard unit</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Respiratory Failure With Hypoxia</condition>
  <arm_group>
    <arm_group_label>NIV/HFNC</arm_group_label>
    <description>patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC/NIV</arm_group_label>
    <description>patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non invasive ventilation and high flow nasal canulae oxygen therapy</intervention_name>
    <description>patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy</description>
    <arm_group_label>HFNC/NIV</arm_group_label>
    <arm_group_label>NIV/HFNC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults referred in ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients referred in ICU&#xD;
&#xD;
          -  with hypoxemic acute respiratory failure due to a community acquired pneumonia&#xD;
             confirmed by chest X ray,&#xD;
&#xD;
          -  with PaO2 &lt; 60mmHg in ambient air, without hypercapnia (PaCO2 &lt; 45 mmHg),&#xD;
&#xD;
          -  requiring more than 6L/min of O2 on admission with high concentration FM, and&#xD;
             justifying HFNC or NIV for the attending ICU physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiogenic pulmonary oedema,&#xD;
&#xD;
          -  moderate to severe underlying respiratory disease including COPD (chronic obstructive&#xD;
             pulmonary disease)&#xD;
&#xD;
          -  contraindication to or failure of previous NIV or HFNC with the need for immediate&#xD;
             invasive ventilation&#xD;
&#xD;
          -  pregnant or breast-feeding women&#xD;
&#xD;
          -  carrier of an implantable defibrillator or pacemaker&#xD;
&#xD;
          -  body mass index (BMI)&gt;50 kg/m2&#xD;
&#xD;
          -  with cutaneous lesion next to the positioning zone of the Pulmovista® (Dräger, Lübeck,&#xD;
             Germany) belt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe GIRAULT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Intensive Care Department, Rouen University Hospital, F-76000 Rouen, France</affiliation>
  </overall_official>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alveolar recruitment</keyword>
  <keyword>electrical impedance tomography</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>high-flow nasal cannula oxygen therapy</keyword>
  <keyword>hypoxemic acute respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>from the first patient enrollment ( 02/22/2016) to publication</ipd_time_frame>
    <ipd_access_criteria>Excel database was shared with biostatisticians for statistical analysis</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

